Clinical Trial

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in subjects with mild, moderate liver impairment and normal liver function, and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-18; most recent amendment 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2024-06-24
Trial Details
NCT Number NCT06376474
Lead Sponsor Ganzhou Hemay Pharmaceutical Co., Ltd
Conditions Psoriasis
Enrollment 24 participants
Start Date 2024-04-28
Primary Completion 2025-12-10 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-04